# Yu Mi Kang on the PCSK9 inhibitor Evolocumab & the FOURIER Trial, Neda Rasouli with insights on semaglutide in symptomatic peripheral artery disease & the STRIDE Trial, and more!

Page: https://stenobird.com/podcast/diabetes-care-on-air-5983699/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more
Text version: https://stenobird.com/podcast/diabetes-care-on-air-5983699/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more.md
Podcast: [Diabetes Care "On Air"](https://stenobird.com/podcast/diabetes-care-on-air-5983699)
Published: 2025-09-05T14:39:00+00:00
Episode link: https://a37ae29a-26fa-4a28-8b27-9beef19d824e.libsyn.com/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more
Audio file: https://traffic.libsyn.com/secure/a37ae29a-26fa-4a28-8b27-9beef19d824e/DCOA_0925_37.mp3?dest-id=3811482
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/diabetes-care-on-air-5983699/episodes/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more
Duration seconds: 2529

## Resource

Welcome to episode no. 35 (September 2025) of Diabetes Care "On Air"—a new and different way to bring the research published in Diabetes Care to life. Join co-hosts Alice Cheng, MD, FRCPC, and Michael Rickels, MD, MS, as they discuss the latest and greatest content in the September 2025 issue of Diabetes Care and beyond. 3:05 Alice is joined by Yu Mi Kang , MD, PhD, endocrinologist at Brigham and Women's Hospital and instructor at Harvard University in Boston. The discuss her article, "Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial," available for free at doi.org/10.2337/dc25-0942 . 14:10 Mike speaks with Neda Rasouli , MD, Professor of Medicine in the Division of Endocrinology, Metabolism, and Diabetes at the University of Anschutz Medical Campus. She shares insights from her article, "Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial," available for free at doi.org/10.2337/dc25-1082 . 27:20 In the "Diabetes Care Rapid Exchange," Alice and Mike wrap up the episode by reviewing several interesting articles in the September 2025 issue of Diabetes Care. Studies highlighted in this segment include: Templeman et al. Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study doi.org/10.2337/dc25-0192 Yau et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease doi.org/10.2337/dc24-2811 Turner et al. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delive…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/diabetes-care-on-air-5983699/episodes/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/diabetes-care-on-air-5983699/yu-mi-kang-on-the-pcsk9-inhibitor-evolocumab-the-fourier-trial-neda-rasouli-with-insights-on-semaglutide-in-symptomatic-peripheral-artery-disease-the-stride-trial-and-more.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.